5 Analysts Have This To Say About Bio-Rad Laboratories

Analysts have recently adjusted their price targets for Bio-Rad Laboratories (BIO), with the average 12-month target decreasing by 10.15% to $313.40 from $348.80, reflecting revised expectations for the company. Wells Fargo, UBS, Citigroup, and RBC Capital have all lowered their price targets, with ratings ranging from Equal-Weight to Outperform, signaling a mixed but generally positive sentiment. Bio-Rad's financial overview indicates a revenue decline of 4.16% but strong net margins, ROE, and ROA compared to industry peers, along with conservative debt management.

Analysis

Bio-Rad Laboratories (NYSE:BIO) has experienced a notable recalibration in analyst expectations over the last three months, with the average 12-month price target declining by 10.15% to $313.40 from $348.80. This adjustment reflects a more cautious outlook, evidenced by several analysts lowering their price targets: Wells Fargo, for instance, revised its Equal-Weight target downwards to $245.00 from $260.00 and in a separate action to $270.00 from $320.00; UBS lowered its Buy target to $310.00 from $355.00; Citigroup reduced its Buy target to $350.00 from $400.00; and RBC Capital adjusted its Outperform target to $392.00 from $409.00. Analyst sentiment has also shifted, with one 'Indifferent' rating recorded in the last 30 days compared to two 'Bullish' and one 'Somewhat Bullish' rating two months prior, though detailed current ratings from these analysts still range from Equal-Weight to Outperform/Buy. Financially, Bio-Rad reported a revenue decline of approximately 4.16% for the three-month period ending March 31, 2025, indicating underperformance relative to Health Care sector peers. Despite this top-line challenge, the company exhibits strong profitability metrics, including a net margin of 10.93%, a return on equity (ROE) of 0.97%, and a return on assets (ROA) of 0.68%, all of which surpass industry benchmarks. Additionally, Bio-Rad maintains conservative debt management with a debt-to-equity ratio of 0.21, below the industry average, while its market capitalization is positioned below industry averages.

Key Decisions for Investors

• Investors should closely monitor upcoming earnings reports for signs of revenue stabilization or recovery, given the recent 4.16% decline and its underperformance against sector peers.
• The consistent downward revisions in analyst price targets, resulting in a current average of $313.40, and the observed shift towards more neutral sentiment suggest that near-term stock appreciation may be limited until a clear catalyst for growth re-emerges.
• Despite revenue headwinds and lowered targets, Bio-Rad's superior net margin, strong ROE and ROA, and low debt-to-equity ratio may appeal to investors prioritizing companies with robust financial health and profitability, potentially offering a defensive quality in a volatile market.